Contact

CleanCap® FLuc mRNA - (L-7602)

CleanCap® Firefly Luciferase mRNA

$304.00
In stock
default
L-7602
Product SKU Unit Size Price Qty
L-7602-100 100 µg
$304.00
L-7602-1000 1 mg
$1,636.00
L-7602-5 5 x 1 mg
$5,803.00
Description

The FLuc mRNA  expresses a luciferase protein, originally isolated from the firefly, Photinus pyralis. FLuc is commonly used in mammalian cell culture to measure both gene expression and cell viability. It emits bioluminescence in the presence of the substrate, luciferin.

This mRNA is capped using CleanCap® Reagent AG, TriLink's patented co-transciptional capping technology, which results in the naturally occurring Cap-1 structure with high capping efficiency. It is manufactured using TriLink’s CleanScript™ method*, polyadenylated, and optimized for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap® Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).

CleanScript™ method is TriLink’s proprietary in vitro transcription process that is optimized to minimize dsRNA formation and increase mRNA activity in vivo.

*Starting April 30th, 2024

Product details
Catalog No L-7602
Purity Passes Agarose Gel Mobility
Length 1922 nucleotides
Base Composition Unmodified bases
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Conversion Factor 40 µg/OD260
Recommended Storage At or below -40°C
Application Reporter Genes
Other Name(s) CleanCap® Firefly Luciferase mRNA
Technical documents

Safety Data Sheet Look-up

L-7602 Product Insert

CleanCap FLuc ORF Sequence

Products FAQS

They all contain an optimal 5′ Cap 1 found in higher eukaryotes for their functionality and stability. They also contain a synthetic 5′ UTR with a strong Kozak sequence for efficient translation and a 3′ UTR derived from mouse alpha-globin. Their key differences lie in the type of CleanCap® analog used and the sequence compositions, which may affect their protein expression and immunogenicity.

 

CleanCap® mRNAs

CleanCap® mRNAs (5moU)

CleanCap® M6 mRNAs (N1MePsU)

Expression system

Mammalian

Mammalian

Mammalian

5′ cap

Cap 1

Cap 1

Cap 1

Cap analog

CleanCap® AG

CleanCap® AG

CleanCap® M6

5′ and 3′ UTRs

Included

Included

Included

Poly(A) tail

120 nt

120 nt

120 nt

Sequence composition

Unmodified uridines

Uridines substituted with 5-methoxyuridines

Uridines substituted with N1-methylpseudouridines

Protein expression

High

High

Highest

Immunogenicity

Normal

Reduced

Lowest

 

It is TriLink’s proprietary in vitro transcription method that produces high-quality, high-yield mRNAs from a broad range of sequences. It has been optimized to minimize dsRNA and improve in vivo protein expression from the resulting mRNAs. Please see here for more information.

Our catalog mRNAs are intended for research use and manufactured with procedures in place to minimize endotoxin exposure. However, they are manufactured outside of a cleanroom and thus are not released with an endotoxin specification.  If you need mRNA released with an endotoxin specification or a higher grade of material, please contact mmrna-services@trilinkbiotech.com.

We recommend storing the mRNAs at -400 C to -800 C. To minimize freeze-thaw cycles, aliquot the sample into single-use quantities on the first usage. If kept under these conditions, our catalog mRNAs have been shown to maintain stability for at least 2 years.

The sequence reported is just the ORF, start codon to stop codon, for our catalog mRNAs. It does not include the proprietary 5′ UTR, 3′ UTR, or the 120-nt poly-A tail. For full mRNA length and the length of the ORF please see the corresponding product insert.

Our catalog mRNAs are purified through DNase treatment to remove DNA templates, diafiltration to remove salts and small molecules, and oligo dT capture to remove impurities and retain species with poly(A) tails. 

We do not carry Cy5-labeled mRNAs as catalog products. You may order them as a custom mRNA by completing this request form.

We use the dot blot test, which is a qualitative test to determine the relative amount of dsRNA present in a sample. Generally, this test is performed to assess dsRNA levels in mRNAs before and after RP-HPLC purification.

We minimize the dsRNA level in our ready-to-use mRNAs by incorporating stringent processes that consist of:

  • In vitro transcription using our proprietary CleanScript™ method or the CleanCap® M6 protocol
  • Multiple post-IVT purification steps

We also assess dsRNA level in the sample by dot blot as part of quality analysis.

We look for a single main band running to approximately the correct length to pass the gel result.  Some factors such as modified NTPs can make a sample run slightly lower than the expected size.  Sometimes, sequence-related factors such as highly repetitive or UTP-rich regions (especially when modified UTP is used) can result in additional bands.  We take account of all these factors to confirm that the mRNA was manufactured appropriately and the band is sequence specific before passing the results.

The fragment analyzer reports the percent of smear with a chromatogram. The smear analysis corresponds to the full-length integrity of an mRNA sample.

We start by cleaving the 5′ end of the mRNAs, then use LCMS to determine the mass of capped and uncapped species by the following formula:

We use 40 as the extinction coefficient for our mRNAs. Assigning a sequence-specific extinction coefficient for mRNA can be problematic due to its dependence on length and sequence composition.  Factors like final buffer and temperature can also impact results.  Thus, it is standard to use 40 for all mRNA species and not to calculate a coefficient for each sequence as you would with an oligonucleotide.

Certificate of analysis

CoA search tool

Intellectual property

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patents and patent pending, see trilinkbiotech.com/legal-notices.

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

References
  1. Li, Bin; Luo, Xiao; Deng, Binbin; Giancola, JoLynn B.; McComb, David W.; Schmittgen, Thomas D.; Dong, Yizhou . Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA.
  2. Marceau, Caleb D.; Puschnik, Andreas S.; Majzoub, Karim; Ooi, Yaw Shin; Brewer, Susan M.; Fuchs, Gabriele; Swaminathan, Kavya; Mata, Miguel A.; Elias, Joshua E.; Sarnow, Peter; Carette, Jan E. . Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens.
  3. Mahiny, Azita Josefine; Karikó, Katalin . Measuring Hematocrit in Mice Injected with In Vitro-Transcribed Erythropoietin mRNA.
  4. Luo, X.; Li, B.; Zhang, X.; Zhao, W.; Bratasz, A.; Deng, B.; McComb, D. W.; Dong, Y. . Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents.
  5. Li, Jiahe; Wang, Wade; He, Yanpu; Li, Yingzhong; Yan, Emily Z.; Zhang, Ketian; Irvine, Darrell J.; Hammond, Paula T. . Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery.
  6. Verbeke, Rein; Lentacker, Ine; Wayteck, Laura; Breckpot, Karine; Van Bockstal, Mieke; Descamps, Benedicte; Vanhove, Christian; De Smedt, Stefaan C.; Dewitte, Heleen . Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.
  7. Prieve, Mary G.; Harvie, Pierrot; Monahan, Sean D.; Roy, Debashish; Li, Allen G.; Blevins, Teri L.; Paschal, Amber E.; Waldheim, Matt; Bell, Eric C.; Galperin, Anna; Ella-Menye, Jean-Rene; Houston, Michael E. . Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency.
  8. Schoellhammer, Carl M.; Lauwers, Gregory Y.; Goettel, Jeremy A.; Oberli, Matthias A.; Cleveland, Cody; Park, June Y.; Minahan, Daniel; Chen, Yiyun; Anderson, Daniel G.; Jaklenec, Ana; Snapper, Scott B.; Langer, Robert; Traverso, Giovanni . Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice.
  9. Jiang, Yuhang; Gaudin, Alice; Zhang, Junwei; Agarwal, Tushar; Song, Eric; Kauffman, Amy C.; Tietjen, Gregory T.; Wang, Yongheng; Jiang, Zhaozhong; Cheng, Christopher J.; Saltzman, W. Mark . A "top-down" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery.
  10. Ball, Rebecca L.; Hajj, Khalid A.; Vizelman, Jamie; Bajaj, Palak; Whitehead, Kathryn A. . Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
  11. Roces, CB;Lou, G;Jain, N;Abraham, S;Thomas, A;Halbert, GW;Perrie, Y; . Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics
  12. Li, L;Long, J;Sang, Y;Wang, X;Zhou, X;Pan, Y;Cao, Y;Huang, H;Yang, Z;Yang, J;Wang, S; . Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid
  13. Romanelli, S; . CRISPR/Cas9 Inducible Gene Knockout in Brown Adipose Tissue
  14. Meyer, RA;Patrick Hussmann, G;Peterson, NC;Luis Santos, J;Tuesca, AD; . A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
  15. Kenjo, E;Hozumi, H;Makita, Y;Iwabuchi, KA;Fujimoto, N;Matsumoto, S;Kimura, M;Amano, Y;Ifuku, M;Naoe, Y;Inukai, N;Hotta, A; . Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
  16. Tanaka, H;Miyama, R;Sakurai, Y;Tamagawa, S;Nakai, Y;Tange, K;Yoshioka, H;Akita, H; . Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles
  17. Ali, S;Dussouillez, C;Padilla, B;Frisch, B;Mason, AJ;Kichler, A; . Design of a new cell penetrating peptide for DNA, siRNA and mRNA delivery
Show more